ArticleAmerican journal of clinical oncology2019

Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status.

Hayeon Kim et al.PubMed ↗Publisher ↗

No numbers read from the abstract.